Amylin, a hormone co-secreted with insulin after meals, regulates blood sugar and appetite by activating three distinct receptors in the brain. Each receptor consists of a calcitonin receptor (CTR) paired with a different receptor activity-modifying protein (RAMP1–3), forming AMY₁R, AMY₂R, and AMY₃R. While these receptors have long been recognized as promising targets for obesity and diabetes therapies, their complex biology has hindered drug discovery.

A new study from the University of Oklahoma, published in Science Signaling , provides the first biochemical and pharmacological framework for understanding how these receptors assemble, dissociate, and signal. Using detergent-solubilized receptors, tagged proteins in live cells, and signaling assays, the team showed that ligands can p

See Full Page